Next Article in Journal
Injury Patterns after Falling down Stairs—High Ratio of Traumatic Brain Injury under Alcohol Influence
Next Article in Special Issue
Changing Metabolic Patterns along the Colorectal Adenoma–Carcinoma Sequence
Previous Article in Journal
Inflammatory Markers and Episodic Memory Functioning in Depressive Disorders
Previous Article in Special Issue
The Association between Early-Life Gut Microbiota and Long-Term Health and Diseases
 
 
Brief Report

Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome

1
Pediatric Unit, Pediatric Emergency Department (DEA), Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
2
Clinical & Research Unit of Clinical Immunology and Vaccinology, Academic Department of Pediatrics (DPUO), Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
3
Chair of Pediatrics, Department of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy
4
The School of Pediatrics, Tor Vergata University, 00133 Rome, Italy
5
Department of Laboratories, Bambino Gesù Children’s Hospital, 00165 Rome, Italy
6
Unit of Microbiology and Diagnostic Immunology, Department of Laboratories, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
7
Unit of Immune and Infectious Diseases, Academic Department of Pediatrics, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Katharina Kurz and Michel Cogné
J. Clin. Med. 2022, 11(3), 694; https://doi.org/10.3390/jcm11030694
Received: 23 December 2021 / Revised: 11 January 2022 / Accepted: 26 January 2022 / Published: 28 January 2022
We aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in young people with Down syndrome (DS), and to compare their humoral immune response with those of the healthy controls (HC). Individuals with DS and HC received the BNT162b2 vaccine. Longitudinal blood samples were collected on the day of vaccination, twenty-one days after the first dose, seven days after the second dose, and six months after the first dose. Both the local and systemic adverse events reported by participants were mild. Pain at the injection site was the most reported local adverse event, while fever was the systemic adverse event. Humoral responses showed a significant increase of anti-S and anti-S trimeric antibody (Ab) levels after both doses of vaccine in both groups. In comparison with HC, Ab levels in individuals with DS were similar at T21, but significantly lower, both in terms anti-S and anti-S trimeric, at T28 (respectively p = 0.0003 and p = 0.0001). At T180 both groups showed a significant reduction of anti-S trimeric Ab levels compared to T28 (p = 0.0004 and p < 0.0001 for DS and HC, respectively). Individuals with DS exhibit a good humoral response to the BNT162b2 vaccine; however, similarly to in HC, the immune response wanes over time. View Full-Text
Keywords: down syndrome; COVID-19; mRNA vaccination; humoral response down syndrome; COVID-19; mRNA vaccination; humoral response
Show Figures

Figure 1

MDPI and ACS Style

Valentini, D.; Cotugno, N.; Scoppola, V.; Di Camillo, C.; Colagrossi, L.; Manno, E.C.; Perno, C.F.; Russo, C.; Palma, P.; Rossi, P.; Villani, A. Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. J. Clin. Med. 2022, 11, 694. https://doi.org/10.3390/jcm11030694

AMA Style

Valentini D, Cotugno N, Scoppola V, Di Camillo C, Colagrossi L, Manno EC, Perno CF, Russo C, Palma P, Rossi P, Villani A. Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. Journal of Clinical Medicine. 2022; 11(3):694. https://doi.org/10.3390/jcm11030694

Chicago/Turabian Style

Valentini, Diletta, Nicola Cotugno, Vittorio Scoppola, Chiara Di Camillo, Luna Colagrossi, Emma Concetta Manno, Carlo Federico Perno, Cristina Russo, Paolo Palma, Paolo Rossi, and Alberto Villani. 2022. "Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome" Journal of Clinical Medicine 11, no. 3: 694. https://doi.org/10.3390/jcm11030694

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop